Search | OpenScholar

Search results

373 results found

A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. Parkinsonism Relat Disord 2020;81:144-150.

Publication: Journal Article

Farbman, ES, CH Waters, PA LeWitt, M Rudinska, M Klingler, A Lee, J Qian, C Oh, and RA Hauser. 2020. “A 12-Month, Dose-Level Blinded Safety and Efficacy Study of Levodopa Inhalation Powder (CVT-301, Inbrija) in Patients With Parkinson’s Disease. Parkinsonism Relat Disord 2020;81:144-150.”. Parkinsonism Relat Disord.

Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr 2020;20:1-10.

Publication: Journal Article

Hauser, RA, JM Meyer, SA Factor, CL Comella, CM Tanner, RM Xavier, SN Caroff, and L Lundt. 2020. “Differentiating Tardive Dyskinesia: A Video-Based Review of Antipsychotic-Induced Movement Disorders in Clinical Practice. CNS Spectr 2020;20:1-10.”. CNS Spectr.

Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Int J Neurosci 2016;126:20-24

Publication: Journal Article

Kumar, R, RA Hauser, J Mostillo, N Dronamraju, A Graf, M Merschemke, and C Kenney. 2016. “Mavoglurant (AFQ056) in Combination With Increased Levodopa Dosages in Parkinson’s Disease Patients. Int J Neurosci 2016;126:20-24”. Int J Neurosci.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015;72:88-95.

Publication: Journal Article

Smith, KM, E Eyal, D Weintraub, and Adagio Investigators. 2015. “Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study: Effects on Nonmotor Symptoms and Tolerability. JAMA Neurol 2015;72:88-95.”. JAMA Neurol.

Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.

Publication: Journal Article

Bega, D, S Kim, Y Zhang, J Elm, J Schneider, R Hauser, A Fraser, and T Simuni. 2015. “Predictors of Functional Decline in Early Parkinson’s Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.”. J Parkinsons Dis.

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:268-75.

Publication: Journal Article

Low, PA, D Robertson, S Gilman, H Kaufmann, W Singer, I Biaggioni, R Freeman, et al. 2014. “Efficacy and Safety of Rifampicin for Multiple System Atrophy: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Neurol 2014;13:268-75.”. Lancet Neurol.

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. Parkinsons Dis. 2021 Feb 19;2021:6638088. doi: 10.1155/2021/6638088. eCollection 2021.PMID: 33688424

Publication: Journal Article

Hauser, RA, G Banisadr, K Vuong, D Freilich, S Fisher, and R D’Souza. 2021. “Real-World Experience With Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. Parkinsons Dis. 2021 Feb 19;2021:6638088. Doi: 10.1155/2021/6638088. ECollection 2021.PMID: 33688424”. Parkonsons Dis.

Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. Evid Based Med 2015;20:17.

Publication: Journal Article

Hauser, RA. 2015. “Initial Choice of Medication Has Little Effect on Short-Term or Long-Term Outcome for Most Patients With Parkinson’s Disease. Evid Based Med 2015;20:17.”. Evid Based Med.

Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.

Publication: Journal Article

Poewe, W, RA Hauser, and A Lang. 2015. “Effects of Rasagiline on the Progression of Nonmotor Scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.”. Mov Disord.

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.

Publication: Journal Article

Hauser, RA, R Pahwa, WA Wargin, CJ Souza-Prien, N McClure, R Johnson, JT Nguyen, R Patni, and GT Went. 2018. “Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.”. Clin Pharmacokinet.

Current search

Search found 373 items
(-) USF Parkinson's Disease and Movement Disorders Center
(-) 2024

Sort by

Filter By Post Date

(-) 2024

Filter By Post Type

Filter By Other Sites

(-) USF Parkinson's Disease and Movement Disorders Center

No filters available

Filter By Taxonomy

No filters available